Illumina, Inc. (NASDAQ:ILMN) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition.

On August 1, 2017, Illumina, Inc. (the "Company") issued a press release announcing financial results for the second quarter ended July2, 2017. The full text of the Company’s press release is attached hereto as Exhibit99.1.

The information furnished to this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.

Item 2.02 Financial Statements and Exhibits.

(d)Exhibits.

99.1Press release dated August 1, 2017, announcing Illumina, Inc.’s financial results for the second quarter ended July2, 2017.

ILLUMINA INC ExhibitEX-99.1 2 a2q17earningsrelease.htm EXHIBIT 99.1 Exhibit Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017San Diego — (BUSINESS WIRE) – August 1,…To view the full exhibit click here
About Illumina, Inc. (NASDAQ:ILMN)
Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets.